Misonidazole is a radiosensitizer that was investigated in clinical trials. It was used in these trials for radiation therapy to cause normally resistant hypoxic tumor cells to become sensitive to the treatment.[1][2]
Names | |
---|---|
IUPAC name
(RS)-1-Methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.033.559 |
EC Number |
|
KEGG | |
MeSH | D008920 |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C7H11N3O4 | |
Molar mass | 201.182 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
See also
editReferences
edit- ^ Meißner, Rebecca; Feketeová, Linda; Illenberger, Eugen; Denifl, Stephan (2019). "Reactions in the Radiosensitizer Misonidazole Induced by Low-Energy (0–10 eV) Electrons". International Journal of Molecular Sciences. 20 (14): 3496. doi:10.3390/ijms20143496. PMC 6678818. PMID 31315268.
- ^ Overgaard, Jens (2011). "Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – A systematic review and meta-analysis". Radiotherapy and Oncology. 100 (1): 22–32. doi:10.1016/j.radonc.2011.03.004. PMID 21511351.